(XLV) Health Care Sector SPDR Fund - Ratings and Ratios
Pharmaceuticals, Biotech, Medical Devices, Provider Services
Dividends
| Dividend Yield | 1.57% |
| Yield on Cost 5y | 2.36% |
| Yield CAGR 5y | 7.97% |
| Payout Consistency | 96.2% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 14.0% |
| Value at Risk 5%th | 22.9% |
| Relative Tail Risk | -0.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -2.26 |
| CAGR/Max DD | 0.33 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.339 |
| Beta | 0.481 |
| Beta Downside | 0.500 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.11% |
| Mean DD | 5.67% |
| Median DD | 5.01% |
Description: XLV Health Care Sector SPDR Fund October 14, 2025
The Health Care Select Sector SPDR® Fund (XLV) seeks to replicate the performance of its underlying index by investing at least 95 % of assets in the constituent securities. The index is composed of companies across pharmaceuticals, health-care equipment & supplies, health-care providers & services, biotechnology, life-sciences tools & services, and health-care technology, and the ETF is classified as a non-diversified fund.
Key quantitative points to note: XLV’s expense ratio stands at 0.12 %, placing it among the lower-cost options in the health-care ETF space; as of the latest reporting period, the fund holds roughly $30 B in assets under management, with the top five holdings (e.g., UnitedHealth Group, Johnson & Johnson, Pfizer, Merck, and AbbVie) together accounting for about 45 % of total net assets. Sector-level drivers include an aging U.S. population, rising Medicare/Medicaid expenditures, and sustained R&D pipelines in biotech, all of which historically support a long-term growth bias for health-care equities.
For a deeper, data-driven look at XLV’s risk-adjusted performance and valuation metrics, the ValueRay platform provides a transparent dashboard that can help you evaluate whether the fund aligns with your investment objectives.
What is the price of XLV shares?
Over the past week, the price has changed by -2.11%, over one month by +7.36%, over three months by +13.79% and over the past year by +7.51%.
Is XLV a buy, sell or hold?
What are the forecasts/targets for the XLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 163.7 | 5.5% |
XLV Fundamental Data Overview November 29, 2025
Beta = 0.68
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 39.01b USD (39.01b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 39.01b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 39.01b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.79% (E(39.01b)/V(39.01b) * Re(7.79%) + (debt-free company))
Discount Rate = 7.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XLV ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle